Positive initial results for srRNA rabies vaccine
Drug Discovery World
FEBRUARY 19, 2024
At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus. Preliminary data show that the surrogate metric of protection (RVNA≥0.5)
Let's personalize your content